People Christopher Geven

Contact

Christopher Geven MD MSc

+31 (0)24 361 67 35
contact

Christopher Geven PhD candidate

The main focus of Christopher's research is a potential new sepsis drug named Adrecizumab. His research involves experimental studies in both animals and humans as well as clinical trials.

read more

Christopher Geven PhD candidate

Christopher Geven completed his MSc in Medicine in 2013. In the year thereafter, he worked as a resident physician at the department of Intensive Care of the Radboudumc. Since December 2014, he is a PhD-candidate at the department of Intensive Care Medicine. The main focus of his research is a potential new sepsis drug named Adrecizumab. His research involves experimental studies in both animals and humans as well as clinical trials.

Personal prizes & awards national & international

  • 2017: RIMLS Poster award

Field of study

Intensive Care

Radboud Institute for Molecular Life Sciences

Our main aim is to achieve a greater understanding of the molecular mechanisms of disease. By integrating fundamental and clinical research, we obtain multifaceted knowledge of (patho)physiological processes. read more